Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NTRB logo NTRB
Upturn stock ratingUpturn stock rating
NTRB logo

Nutriband Inc (NTRB)

Upturn stock ratingUpturn stock rating
$9.91
Last Close (24-hour delay)
Profit since last BUY28.53%
upturn advisory
Consider higher Upturn Star rating
BUY since 22 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: NTRB (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $15

1 Year Target Price $15

Analysts Price Target For last 52 week
$15 Target price
52w Low $3.72
Current$9.91
52w High $11.78

Analysis of Past Performance

Type Stock
Historic Profit -41.16%
Avg. Invested days 32
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 110.30M USD
Price to earnings Ratio -
1Y Target Price 15
Price to earnings Ratio -
1Y Target Price 15
Volume (30-day avg) 1
Beta 1.2
52 Weeks Range 3.72 - 11.78
Updated Date 07/4/2025
52 Weeks Range 3.72 - 11.78
Updated Date 07/4/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.9

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -211.78%

Management Effectiveness

Return on Assets (TTM) -36.45%
Return on Equity (TTM) -108.02%

Valuation

Trailing PE -
Forward PE 370.37
Enterprise Value 107619332
Price to Sales(TTM) 45.99
Enterprise Value 107619332
Price to Sales(TTM) 45.99
Enterprise Value to Revenue 44.87
Enterprise Value to EBITDA -4.55
Shares Outstanding 11130300
Shares Floating 4420276
Shares Outstanding 11130300
Shares Floating 4420276
Percent Insiders 76.37
Percent Institutions 2.9

ai summary icon Upturn AI SWOT

Nutriband Inc

stock logo

Company Overview

overview logo History and Background

Nutriband Inc. (NTRB) is a Nevada corporation specializing in transdermal drug delivery technology. Initially focused on abuse-deterrent transdermal patches, the company has expanded its product line. Founded with a commitment to innovative solutions for medication adherence and safety.

business area logo Core Business Areas

  • Transdermal Drug Delivery: Development and commercialization of transdermal patches for various pharmaceutical and consumer health applications.
  • Abuse-Deterrent Technology: Formulation of transdermal patches designed to deter abuse and misuse of controlled substances.
  • Nutritional Supplements: Development of innovative supplements using transdermal and oral delivery methods.

leadership logo Leadership and Structure

Gaston F. Khoury serves as the Chairman and CEO. The company operates with a small team focused on R&D, manufacturing partnerships, and regulatory approvals.

Top Products and Market Share

overview logo Key Offerings

  • AvertRx Abuse-Deterrent Patch Technology: Abuse-deterrent transdermal patch technology designed to make opioid patches more difficult to misuse. No market share data is available. Competitors include pharmaceutical companies with abuse-deterrent opioid formulations.
  • Nutriband Patch: A transdermal patch delivery system for supplements and OTC medications. Limited market share data is available. Competitors include companies producing vitamins and nutritional supplements, and other transdermal patch manufacturers.

Market Dynamics

industry overview logo Industry Overview

The transdermal drug delivery market is experiencing growth, driven by patient preference, ease of use, and controlled drug release. The nutritional supplement market is also experiencing growth, fueled by increased consumer awareness of health and wellness.

Positioning

Nutriband Inc. positions itself as an innovator in transdermal technology, particularly in abuse-deterrent and consumer health applications. Its competitive advantage lies in its patented AvertRx technology and focus on niche markets.

Total Addressable Market (TAM)

The transdermal drug delivery TAM is estimated to be in the billions of dollars. The nutritional supplements market is also a multi-billion dollar market. Nutriband Inc. aims to capture a portion of these markets through its niche products and patented technology.

Upturn SWOT Analysis

Strengths

  • Patented AvertRx abuse-deterrent technology
  • Focus on innovative transdermal solutions
  • Potential for partnerships with larger pharmaceutical companies
  • Established manufacturing partners.

Weaknesses

  • Limited financial resources
  • Small size and limited market reach
  • Reliance on partnerships for manufacturing and distribution
  • History of operating losses and limited revenue.

Opportunities

  • Increasing demand for abuse-deterrent formulations
  • Growing market for transdermal drug delivery
  • Potential for expansion into new therapeutic areas
  • Collaboration with major pharmaceutical companies.

Threats

  • Competition from larger pharmaceutical companies
  • Regulatory hurdles and lengthy approval processes
  • Patent infringement risks
  • Potential product liability claims.

Competitors and Market Share

competitor logo Key Competitors

  • TEVA
  • MYL
  • ALK

Competitive Landscape

Nutriband Inc. faces intense competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its patented technology and focus on niche markets.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited by the company's focus on R&D and regulatory approvals.

Future Projections: Future growth projections depend on the successful commercialization of its products and partnerships.

Recent Initiatives: Recent initiatives include pursuing regulatory approvals for AvertRx, expanding its product line, and establishing manufacturing and distribution agreements.

Summary

Nutriband Inc. is a small, early-stage company with innovative transdermal technology, but it faces significant financial and competitive challenges. The company's success depends on securing regulatory approvals, establishing strategic partnerships, and successfully commercializing its products. While the patented AvertRx technology holds promise, the company's limited resources and intense competition pose risks. Strong market growth in Transdermal technology is promising and they need to capture more market share.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Nutriband Inc. SEC filings (10-K, 10-Q)
  • Industry reports on transdermal drug delivery
  • Market research on abuse-deterrent formulations

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Market share data is approximate and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nutriband Inc

Exchange NASDAQ
Headquaters Orlando, FL, United States
IPO Launch date 2017-11-30
Founder, CEO & Director Mr. Gareth Sheridan
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.